SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 4 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar pchop123 (80.25) Submitted: 12/4/2012 10:25:24 AM : Outperform Start Price: $4.43 SCLN Score: -5.23

potential new acquisition may be in the works

Featured Broker Partners


Advertisement